Full Breakdown
Genicular Artery Embolization Halves Knee Pain in Osteoarthritis Patients
6/24/2026, 12:35:12 AM
Background: Osteoarthritis Burden and Treatment Gap
Osteoarthritis of the knee affects over 595 million people globally (Lancet Rheumatology 2023) and is a leading cause of disability. Conventional therapies—physiotherapy, anti-inflammatory drugs, corticosteroid injections—often fail, while joint replacement is unsuitable for many, leaving a substantial treatment gap.
Study Design and Participants
The prospective study at Charité University Hospital in Berlin enrolled 194 adults (median age 69, median BMI 28.4), 114 women and 80 men. The investigation was led by Dr. Florian Nima Fleckenstein, deputy head of Interventional Radiology at Charité, together with a multidisciplinary team of radiologists and orthopedic surgeons. Forty-five participants received bilateral treatment, totaling 239 GAE procedures performed under local anaesthesia with rapidly resorbable gelatin-based microspheres.
Results: Pain Relief, Functional Gains, Safety
Pain, measured on a 0-10 Numeric Rating Scale, fell from a median of 7 pre-procedure to 3 at 12 months—a 4-point drop exceeding the 2-point clinical threshold. At one year, 80 % achieved the minimum clinically important difference for pain, and 55-80 % met meaningful improvement across all KOOS subdomains. Adverse events were minor: transient skin discoloration in 6.3 % (15/239) resolved within 24 hours; no moderate or severe complications occurred.
Official Statements & Responses
The authors note that the resorbable microspheres yield a cleaner side-effect profile than permanent agents and stress the absence of moderate or severe complications. They acknowledge the single-center, uncontrolled design and call for larger randomized trials before GAE can become standard care.
Criticism & Opposition
Critics point to the absence of a control arm, arguing that without randomization the true magnitude of benefit cannot be isolated from placebo effects.
Conflicting Reports & Gaps
The study provides no outcomes beyond 12 months, leaving long-term durability unknown, and excludes patients who responded to conservative therapy, limiting applicability to the broader osteoarthritis population.
Verbatim Quotes
- “For many patients with knee osteoarthritis, there is a real treatment gap today,” — Florian Nima Fleckenstein, M.D., deputy head of Interventional Radiology Campus Mitte, Charité — Universitätsmedizin Berlin
- “GAE is a whole new treatment regimen that targets abnormal hypervascularity around the joint and, in turn, modulates the pathological neurovascular environment,” — Florian Nima Fleckenstein, M.D.
- “Our study demonstrates that GAE using rapidly resorbable gelatin-based microspheres is a safe, minimally invasive therapy that provides meaningful pain relief and functional improvement in participants with osteoarthritis-related knee symptoms for at least 12 months,” — Florian Nima Fleckenstein, M.D.
- “By embolizing the pathological vessels, we're able to normalize the vessel structure -- and, in turn, the neuronal structure of the knee.” — Florian Nima Fleckenstein, M.D.
What’s Next: Future Research and Clinical Implications
The team plans randomized controlled trials to confirm efficacy, assess durability beyond one year, and compare GAE with injections and joint replacement, potentially establishing a new minimally invasive option.
